Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Latest filing published 21 Sept 2023 for Paratek Pharmaceuticals, Inc.. Read the official filing
Filing timeline
BuySaleTimothy R. Franson
Insider track record
Disclosed buys
1
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Timothy R. Franson: trading record in brief
This profile gathers the share dealings of Timothy R. Franson across 2 companies, led by Paratek Pharmaceuticals, Inc. and Cidara Therapeutics, Inc. We count 5 filings; the first trade dates from 13 September 2021 and the latest from 21 September 2023.
Market trades split into 1 purchase (€13k) and 1 sale (€12k). Purchases outweigh sales by €230. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants. So far in 2023, the count stands at no purchases and 1 sale.
The latest filing, published on 21 September 2023, reports a transaction in Paratek Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 1,860 days ago, on 14 September 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Timothy R. Franson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
52,000 sharesCommon StockSEC:0000899243-23-019355:0
7,000 shares@ US$1.88100.0% of flowCommon StockSEC:0000904454-23-000176:0
20,000 shares0Common StockSEC:0000904454-23-000103:0
20,000 shares0Common StockSEC:0000904454-22-000165:0
7,000 shares@ US$2.1175100.0% of flowCommon StockSEC:0001610618-21-000084:0
Canonical exit: 12 Dec 2021 (T+90)
5 of 5 declarations
